Merck & Co., Inc.
A maker of prescription medicines and animal health products, Merck produces well-known drugs like the cancer treatment Keytruda and the HPV vaccine Gardasil, along with livestock and pet-care vaccines used by doctors, veterinarians, and farmers. Founded in 1891 as the American branch of a German family firm, the company was seized during World War I and later bought back, becoming an independent U.S. company that today goes by the name MSD outside North America. A fun quirk: its blockbuster Keytruda nearly got shelved — researchers originally set out to calm the immune system, not fight cancer.
Granted 2.96M · Sold 2.84M
Granted 832.6K · Sold 593.4K
Granted 593.6K · Sold 552.9K
Granted 451.6K · Sold 343.0K
Granted 42.1K · Sold 39.8K
Granted 150.7K · Sold 40.0K
Granted 122.6K · Sold 40.0K
Granted 173.0K · Sold 98.6K
Granted 186.9K · Sold 184.1K
Granted 462.4K · Sold 430.9K
Granted 14.7K
Granted 105.8K · Sold 96.3K
Granted 552
Granted 84.7K · Sold 72.9K
Granted 63.5K · Sold 28.6K
Granted 12.3K · Bought 409 · Sold 6.1K
Granted 114.0K · Sold 95.5K
Bought 15.0K
Granted 24.8K
Granted 14.8K · Sold 10.7K
Granted 8.3K
Granted 4.0K
Bought 2.8K
Granted 2.5K
Granted 9.4K · Sold 9.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Frazier Kenneth CExecutive Chair, Director · 32 transactions | +39.7% | 1.65Mas of Nov 2022 | 2.96M | — | 2.84M |
| Davis Robert MChairman, CEO & President, Director · 21 transactions | +106.9% | 450.4K | 832.6K | — | 593.4K |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth · 23 transactions | +40.8% | 325.7K | 593.6K | — | 552.9K |
| Chattopadhyay SanatExe V-P & Pres. MMD · 23 transactions | — | 258.3K | 451.6K | — | 343.0K |
| Clyburn FrankEVP & Pres ? Human Health · 5 transactions | +44.3% | 138.6Kas of Nov 2021 | 42.1K | — | 39.8K |
| Guindo ChirfiEVP, Access, Policy & Comms · 13 transactions | — | 124.3K | 150.7K | — | 40.0K |
| Li Dean YExecutive VP & President, MRL · 18 transactions | +652.6% | 94.4K | 122.6K | — | 40.0K |
| Litchfield CarolineEVP & CFO · 19 transactions | +367.6% | 92.3K | 173.0K | — | 98.6K |
| Mizell StevenEVP, Chief HR Officer · 28 transactions | +220.6% | 74.3Kas of Feb 2024 | 186.9K | — | 184.1K |
| Zachary JenniferEVP, General Counsel · 23 transactions | +107.7% | 70.9K | 462.4K | — | 430.9K |
| Klobuchar Michael AEVP - Chief Strategy Officer · 15 transactions | — | 49.5Kas of May 2024 | 14.7K | — | — |
| Gerberding Julie L.EVP, Chief Patient Officer · 6 transactions | +24.4% | 48.7Kas of Feb 2022 | 105.8K | — | 96.3K |
| Maraldo David R.EVP & Pres. MMD · 2 transactions | — | 44.9K | 552 | — | — |
| Karachun Rita ASr. VP Fince-Global Controller · 21 transactions | +24.5% | 44.6Kas of May 2023 | 84.7K | — | 72.9K |
| Williams David MichaelEVP,Chief Info&Digital Officer · 26 transactions | +474.7% | 31.7K | 63.5K | — | 28.6K |
| Romanelli JosephPresident, Human Health Int?l · 20 transactions | — | 28.7K | 12.3K | 409 | 6.1K |
| Oosthuizen Johannes JacobusEVP, Oncology & Int?l · 38 transactions | — | 21.9K | 114.0K | — | 95.5K |
| Baker Douglas M JrDirector · 1 transaction | — | 16.0K | — | 15.0K | — |
| Larson Betty DEVP, Chief HR Officer · 6 transactions | — | 13.8K | 24.8K | — | — |
| Smart Dalton E. IIISVP Fin. - Global Controller · 20 transactions | — | 9.4K | 14.8K | — | 10.7K |
| Smart DaltonSVP Fin. - Global Controller · 10 transactions | — | 7.0Kas of Jan 2025 | 8.3K | — | — |
| LeCointe-Cephas LisaSVP Chief Ethics & Com Officer · 12 transactions | +59% | 4.2Kas of May 2023 | 4.0K | — | — |
| Thulin Inge GDirector · 1 transaction | +2832.9% | 2.9K | — | 2.8K | — |
| Garay ArpaSVP Human Health Global Mktg. · 6 transactions | — | 2.4Kas of May 2022 | 2.5K | — | — |
| Downing Cristal NChief Comm. & Public Afrs Ofcr · 3 transactions | — | 0 | 9.4K | — | 9.4K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -5.46M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.